AustralieFrV1, PascalFrancis, Curation, bibRecord, 004527

Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study

Identifieur interne : 004527 ( PascalFrancis/Curation ); précédent : 004526; suivant : 004528

Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study

Auteurs : Kerryn E. Pike [Australie] ; Kathryn A. Ellis [Australie] ; Victor L. Villemagne [Australie] ; Norm Good [Australie] ; Gael Chetelat [Australie, France] ; David Ames [Australie] ; Cassandra Szoeke [Australie] ; Simon M. Laws [Australie] ; Giuseppe Verdile [Australie] ; Ralph N. Martins [Australie] ; Colin L. Masters [Australie] ; Christopher C. Rowe [Australie]

Source :

Neuropsychologia [ 0028-3932 ] ; 2011.

RBID : Pascal:11-0384044

Descripteurs français

Pascal (Inist)
- Cognition, Protéine amyloïde β, Démence d'Alzheimer, Mémoire, Sénescence, Vieillissement, Tomoscintigraphie, Imagerie médicale, Homme, Personne âgée.
Wicri :
- topic : Homme, Personne âgée.

English descriptors

KwdEn :
- Ageing, Alzheimer disease, Cognition, Elderly, Emission tomography, Human, Medical imagery, Memory, Senescence, β Amyloid protein.

Abstract

The 'preclinical' phase of Alzheimer's disease is a future target for treatment, but additional research is essential to understand the relationship between β-amyloid burden and cognition during this time. We investigated this relationship using a large sample of apparently healthy older adults (N₌ 177), which also enabled examination of whether the relationship differed according to age, gender, years of education, apolipoprotein E status, and the presence of subjective memory complaints. In addition to episodic memory, a range of cognitive measures (global cognition, semantic memory, visuospatial performance, and executive function) were examined. Participants were aged over 60 years with no objective cognitive impairment and came from the imaging arm of the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study of ageing. ¹¹C-PiB PET was used to measure β-amyloid burden and a PiB'cut-off' level of 1.5 was used to separate participants with low PiB retention from those with high PiB retention. Thirty-three percent of participants had a PiB positive scan. PiB positive participants were 5 years older, twice as likely to carry an apolipoprotein E ε4 allele, and their composite episodic memory was 0.26 SD worse than PiB negative volunteers. Linear regressions with β-amyloid burden as a dichotomous predictor, revealed an interaction between β-amyloid burden and gender, as well as age and education effects, in predicting episodic memory and visuospatial performance. In females, but not in males, increased β-amyloid was related to worse episodic memory and visuospatial performance. Furthermore, an interaction between β-amyloid burden and APOE status was found in predicting visuospatial performance, whereby there was a trend for increased β-amyloid to relate to worse visuospatial performance for those without an APOE ε4 allele. There were no other main or interaction effects of β-amyloid on any of the other composite cognitive measures. These cross-sectional findings suggest that β-amyloid burden does not have a large effect on cognition in this subset of apparently healthy older people. The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid.

A01	`01`	`1`		`@0 0028-3932`
A02	`01`			`@0 NUPSA6`
A03		`1`		`@0 Neuropsychologia`
A05				`@2 49`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study`
A11	`01`	`1`		`@1 PIKE (Kerryn E.)`
A11	`02`	`1`		`@1 ELLIS (Kathryn A.)`
A11	`03`	`1`		`@1 VILLEMAGNE (Victor L.)`
A11	`04`	`1`		`@1 GOOD (Norm)`
A11	`05`	`1`		`@1 CHETELAT (Gael)`
A11	`06`	`1`		`@1 AMES (David)`
A11	`07`	`1`		`@1 SZOEKE (Cassandra)`
A11	`08`	`1`		`@1 LAWS (Simon M.)`
A11	`09`	`1`		`@1 VERDILE (Giuseppe)`
A11	`10`	`1`		`@1 MARTINS (Ralph N.)`
A11	`11`	`1`		`@1 MASTERS (Colin L.)`
A11	`12`	`1`		`@1 ROWE (Christopher C.)`
A14	`01`			`@1 Department of Nuclear Medicine, Centre for PET, Austin Health @2 Heidelberg, VIC @3 AUS @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 12 aut.`
A14	`02`			`@1 Mental Health Research Institute @2 Parkville, VIC @3 AUS @Z 1 aut. @Z 3 aut. @Z 11 aut.`
A14	`03`			`@1 Centre for Neurosciences, University of Melbourne @2 Parkville, VIC @3 AUS @Z 1 aut. @Z 3 aut. @Z 11 aut.`
A14	`04`			`@1 School of Psychological Science, La Trobe University @2 Bundoora, VIC @3 AUS @Z 1 aut.`
A14	`05`			`@1 Department of Psychiatry, University of Melbourne @2 Parkville, VIC @3 AUS @Z 2 aut. @Z 6 aut.`
A14	`06`			`@1 CSIRO Mathematics, Informatics and Statistics, Australian E-Health Research Centre @2 Herston, QLD @3 AUS @Z 4 aut.`
A14	`07`			`@1 Inserm-EPHE-Université de Caen/Basse-Normandie, Unite U923, GIP Cyceron, CHU Côte de Nacre @2 Caen @3 FRA @Z 5 aut.`
A14	`08`			`@1 National Ageing Research Institute @2 Parkville, VIC @3 AUS @Z 6 aut.`
A14	`09`			`@1 CSIRO Neurodegenerative Disease, Mental Disorders & Brain Health, Preventative Health Flagship, CSIRO Molecular and Health Technologies @2 Parkville, VIC @3 AUS @Z 7 aut.`
A14	`10`			`@1 Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University @2 Joondalup, Western Australia @3 AUS @Z 8 aut. @Z 9 aut. @Z 10 aut.`
A14	`11`			`@1 Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) @2 Perth, Western Australia @3 AUS @Z 8 aut. @Z 9 aut. @Z 10 aut.`
A14	`12`			`@1 Department of Medicine, University of Melbourne @2 Parkville, VIC @3 AUS @Z 12 aut.`
A20				`@1 2384-2390`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 11143 @5 354000508504460110`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 11-0384044`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuropsychologia`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The 'preclinical' phase of Alzheimer's disease is a future target for treatment, but additional research is essential to understand the relationship between β-amyloid burden and cognition during this time. We investigated this relationship using a large sample of apparently healthy older adults (N₌ 177), which also enabled examination of whether the relationship differed according to age, gender, years of education, apolipoprotein E status, and the presence of subjective memory complaints. In addition to episodic memory, a range of cognitive measures (global cognition, semantic memory, visuospatial performance, and executive function) were examined. Participants were aged over 60 years with no objective cognitive impairment and came from the imaging arm of the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study of ageing. ¹¹C-PiB PET was used to measure β-amyloid burden and a PiB'cut-off' level of 1.5 was used to separate participants with low PiB retention from those with high PiB retention. Thirty-three percent of participants had a PiB positive scan. PiB positive participants were 5 years older, twice as likely to carry an apolipoprotein E ε4 allele, and their composite episodic memory was 0.26 SD worse than PiB negative volunteers. Linear regressions with β-amyloid burden as a dichotomous predictor, revealed an interaction between β-amyloid burden and gender, as well as age and education effects, in predicting episodic memory and visuospatial performance. In females, but not in males, increased β-amyloid was related to worse episodic memory and visuospatial performance. Furthermore, an interaction between β-amyloid burden and APOE status was found in predicting visuospatial performance, whereby there was a trend for increased β-amyloid to relate to worse visuospatial performance for those without an APOE ε4 allele. There were no other main or interaction effects of β-amyloid on any of the other composite cognitive measures. These cross-sectional findings suggest that β-amyloid burden does not have a large effect on cognition in this subset of apparently healthy older people. The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid.
C02	`01`	`X`		`@0 002B18C13`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Cognition @5 01`
C03	`01`	`X`	`ENG`	`@0 Cognition @5 01`
C03	`01`	`X`	`SPA`	`@0 Cognición @5 01`
C03	`02`	`X`	`FRE`	`@0 Protéine amyloïde β @5 02`
C03	`02`	`X`	`ENG`	`@0 β Amyloid protein @5 02`
C03	`02`	`X`	`SPA`	`@0 Proteína amiloide β @5 02`
C03	`03`	`X`	`FRE`	`@0 Démence d'Alzheimer @5 03`
C03	`03`	`X`	`ENG`	`@0 Alzheimer disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Demencia Alzheimer @5 03`
C03	`04`	`X`	`FRE`	`@0 Mémoire @5 04`
C03	`04`	`X`	`ENG`	`@0 Memory @5 04`
C03	`04`	`X`	`SPA`	`@0 Memoria @5 04`
C03	`05`	`X`	`FRE`	`@0 Sénescence @5 05`
C03	`05`	`X`	`ENG`	`@0 Senescence @5 05`
C03	`05`	`X`	`SPA`	`@0 Senescencia @5 05`
C03	`06`	`X`	`FRE`	`@0 Vieillissement @5 06`
C03	`06`	`X`	`ENG`	`@0 Ageing @5 06`
C03	`06`	`X`	`SPA`	`@0 Envejecimiento @5 06`
C03	`07`	`X`	`FRE`	`@0 Tomoscintigraphie @5 07`
C03	`07`	`X`	`ENG`	`@0 Emission tomography @5 07`
C03	`07`	`X`	`SPA`	`@0 Tomocentelleografía @5 07`
C03	`08`	`X`	`FRE`	`@0 Imagerie médicale @5 08`
C03	`08`	`X`	`ENG`	`@0 Medical imagery @5 08`
C03	`08`	`X`	`SPA`	`@0 Imaginería médica @5 08`
C03	`09`	`X`	`FRE`	`@0 Homme @5 18`
C03	`09`	`X`	`ENG`	`@0 Human @5 18`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 18`
C03	`10`	`X`	`FRE`	`@0 Personne âgée @5 19`
C03	`10`	`X`	`ENG`	`@0 Elderly @5 19`
C03	`10`	`X`	`SPA`	`@0 Anciano @5 19`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 40`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 40`
N21				`@1 262`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A17
to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002205

Links to Exploration step

Pascal:11-0384044

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study</title>
<author><name sortKey="Pike, Kerryn E" sort="Pike, Kerryn E" uniqKey="Pike K" first="Kerryn E." last="Pike">Kerryn E. Pike</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>School of Psychological Science, La Trobe University</s1>
<s2>Bundoora, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Ellis, Kathryn A" sort="Ellis, Kathryn A" uniqKey="Ellis K" first="Kathryn A." last="Ellis">Kathryn A. Ellis</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Villemagne, Victor L" sort="Villemagne, Victor L" uniqKey="Villemagne V" first="Victor L." last="Villemagne">Victor L. Villemagne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Good, Norm" sort="Good, Norm" uniqKey="Good N" first="Norm" last="Good">Norm Good</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>CSIRO Mathematics, Informatics and Statistics, Australian E-Health Research Centre</s1>
<s2>Herston, QLD</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Chetelat, Gael" sort="Chetelat, Gael" uniqKey="Chetelat G" first="Gael" last="Chetelat">Gael Chetelat</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Inserm-EPHE-Université de Caen/Basse-Normandie, Unite U923, GIP Cyceron, CHU Côte de Nacre</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ames, David" sort="Ames, David" uniqKey="Ames D" first="David" last="Ames">David Ames</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>National Ageing Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Szoeke, Cassandra" sort="Szoeke, Cassandra" uniqKey="Szoeke C" first="Cassandra" last="Szoeke">Cassandra Szoeke</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>CSIRO Neurodegenerative Disease, Mental Disorders & Brain Health, Preventative Health Flagship, CSIRO Molecular and Health Technologies</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Laws, Simon M" sort="Laws, Simon M" uniqKey="Laws S" first="Simon M." last="Laws">Simon M. Laws</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Verdile, Giuseppe" sort="Verdile, Giuseppe" uniqKey="Verdile G" first="Giuseppe" last="Verdile">Giuseppe Verdile</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Martins, Ralph N" sort="Martins, Ralph N" uniqKey="Martins R" first="Ralph N." last="Martins">Ralph N. Martins</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Masters, Colin L" sort="Masters, Colin L" uniqKey="Masters C" first="Colin L." last="Masters">Colin L. Masters</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Rowe, Christopher C" sort="Rowe, Christopher C" uniqKey="Rowe C" first="Christopher C." last="Rowe">Christopher C. Rowe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Medicine, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0384044</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0384044 INIST</idno>
<idno type="RBID">Pascal:11-0384044</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A17</idno>
<idno type="stanalyst">FRANCIS 11-0384044 INIST</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002205</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004527</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study</title>
<author><name sortKey="Pike, Kerryn E" sort="Pike, Kerryn E" uniqKey="Pike K" first="Kerryn E." last="Pike">Kerryn E. Pike</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>School of Psychological Science, La Trobe University</s1>
<s2>Bundoora, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Ellis, Kathryn A" sort="Ellis, Kathryn A" uniqKey="Ellis K" first="Kathryn A." last="Ellis">Kathryn A. Ellis</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Villemagne, Victor L" sort="Villemagne, Victor L" uniqKey="Villemagne V" first="Victor L." last="Villemagne">Victor L. Villemagne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Good, Norm" sort="Good, Norm" uniqKey="Good N" first="Norm" last="Good">Norm Good</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>CSIRO Mathematics, Informatics and Statistics, Australian E-Health Research Centre</s1>
<s2>Herston, QLD</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Chetelat, Gael" sort="Chetelat, Gael" uniqKey="Chetelat G" first="Gael" last="Chetelat">Gael Chetelat</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Inserm-EPHE-Université de Caen/Basse-Normandie, Unite U923, GIP Cyceron, CHU Côte de Nacre</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ames, David" sort="Ames, David" uniqKey="Ames D" first="David" last="Ames">David Ames</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>National Ageing Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Szoeke, Cassandra" sort="Szoeke, Cassandra" uniqKey="Szoeke C" first="Cassandra" last="Szoeke">Cassandra Szoeke</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>CSIRO Neurodegenerative Disease, Mental Disorders & Brain Health, Preventative Health Flagship, CSIRO Molecular and Health Technologies</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Laws, Simon M" sort="Laws, Simon M" uniqKey="Laws S" first="Simon M." last="Laws">Simon M. Laws</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Verdile, Giuseppe" sort="Verdile, Giuseppe" uniqKey="Verdile G" first="Giuseppe" last="Verdile">Giuseppe Verdile</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Martins, Ralph N" sort="Martins, Ralph N" uniqKey="Martins R" first="Ralph N." last="Martins">Ralph N. Martins</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Masters, Colin L" sort="Masters, Colin L" uniqKey="Masters C" first="Colin L." last="Masters">Colin L. Masters</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Rowe, Christopher C" sort="Rowe, Christopher C" uniqKey="Rowe C" first="Christopher C." last="Rowe">Christopher C. Rowe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Medicine, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuropsychologia</title>
<title level="j" type="abbreviated">Neuropsychologia</title>
<idno type="ISSN">0028-3932</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuropsychologia</title>
<title level="j" type="abbreviated">Neuropsychologia</title>
<idno type="ISSN">0028-3932</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ageing</term>
<term>Alzheimer disease</term>
<term>Cognition</term>
<term>Elderly</term>
<term>Emission tomography</term>
<term>Human</term>
<term>Medical imagery</term>
<term>Memory</term>
<term>Senescence</term>
<term>β Amyloid protein</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cognition</term>
<term>Protéine amyloïde β</term>
<term>Démence d'Alzheimer</term>
<term>Mémoire</term>
<term>Sénescence</term>
<term>Vieillissement</term>
<term>Tomoscintigraphie</term>
<term>Imagerie médicale</term>
<term>Homme</term>
<term>Personne âgée</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The 'preclinical' phase of Alzheimer's disease is a future target for treatment, but additional research is essential to understand the relationship between β-amyloid burden and cognition during this time. We investigated this relationship using a large sample of apparently healthy older adults (N<sub>=</sub>
 177), which also enabled examination of whether the relationship differed according to age, gender, years of education, apolipoprotein E status, and the presence of subjective memory complaints. In addition to episodic memory, a range of cognitive measures (global cognition, semantic memory, visuospatial performance, and executive function) were examined. Participants were aged over 60 years with no objective cognitive impairment and came from the imaging arm of the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study of ageing. <sup>11</sup>
C-PiB PET was used to measure β-amyloid burden and a PiB'cut-off' level of 1.5 was used to separate participants with low PiB retention from those with high PiB retention. Thirty-three percent of participants had a PiB positive scan. PiB positive participants were 5 years older, twice as likely to carry an apolipoprotein E ε4 allele, and their composite episodic memory was 0.26 SD worse than PiB negative volunteers. Linear regressions with β-amyloid burden as a dichotomous predictor, revealed an interaction between β-amyloid burden and gender, as well as age and education effects, in predicting episodic memory and visuospatial performance. In females, but not in males, increased β-amyloid was related to worse episodic memory and visuospatial performance. Furthermore, an interaction between β-amyloid burden and APOE status was found in predicting visuospatial performance, whereby there was a trend for increased β-amyloid to relate to worse visuospatial performance for those without an APOE ε4 allele. There were no other main or interaction effects of β-amyloid on any of the other composite cognitive measures. These cross-sectional findings suggest that β-amyloid burden does not have a large effect on cognition in this subset of apparently healthy older people. The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3932</s0>
</fA01>
<fA02 i1="01"><s0>NUPSA6</s0>
</fA02>
<fA03 i2="1"><s0>Neuropsychologia</s0>
</fA03>
<fA05><s2>49</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PIKE (Kerryn E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ELLIS (Kathryn A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VILLEMAGNE (Victor L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GOOD (Norm)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHETELAT (Gael)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>AMES (David)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SZOEKE (Cassandra)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LAWS (Simon M.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>VERDILE (Giuseppe)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MARTINS (Ralph N.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MASTERS (Colin L.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>ROWE (Christopher C.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for PET, Austin Health</s1>
<s2>Heidelberg, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Mental Health Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Centre for Neurosciences, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>School of Psychological Science, La Trobe University</s1>
<s2>Bundoora, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>CSIRO Mathematics, Informatics and Statistics, Australian E-Health Research Centre</s1>
<s2>Herston, QLD</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Inserm-EPHE-Université de Caen/Basse-Normandie, Unite U923, GIP Cyceron, CHU Côte de Nacre</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>National Ageing Research Institute</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>CSIRO Neurodegenerative Disease, Mental Disorders & Brain Health, Preventative Health Flagship, CSIRO Molecular and Health Technologies</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences, Edith Cowan University</s1>
<s2>Joondalup, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Medicine, University of Melbourne</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>2384-2390</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>11143</s2>
<s5>354000508504460110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0384044</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuropsychologia</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The 'preclinical' phase of Alzheimer's disease is a future target for treatment, but additional research is essential to understand the relationship between β-amyloid burden and cognition during this time. We investigated this relationship using a large sample of apparently healthy older adults (N<sub>=</sub>
 177), which also enabled examination of whether the relationship differed according to age, gender, years of education, apolipoprotein E status, and the presence of subjective memory complaints. In addition to episodic memory, a range of cognitive measures (global cognition, semantic memory, visuospatial performance, and executive function) were examined. Participants were aged over 60 years with no objective cognitive impairment and came from the imaging arm of the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study of ageing. <sup>11</sup>
C-PiB PET was used to measure β-amyloid burden and a PiB'cut-off' level of 1.5 was used to separate participants with low PiB retention from those with high PiB retention. Thirty-three percent of participants had a PiB positive scan. PiB positive participants were 5 years older, twice as likely to carry an apolipoprotein E ε4 allele, and their composite episodic memory was 0.26 SD worse than PiB negative volunteers. Linear regressions with β-amyloid burden as a dichotomous predictor, revealed an interaction between β-amyloid burden and gender, as well as age and education effects, in predicting episodic memory and visuospatial performance. In females, but not in males, increased β-amyloid was related to worse episodic memory and visuospatial performance. Furthermore, an interaction between β-amyloid burden and APOE status was found in predicting visuospatial performance, whereby there was a trend for increased β-amyloid to relate to worse visuospatial performance for those without an APOE ε4 allele. There were no other main or interaction effects of β-amyloid on any of the other composite cognitive measures. These cross-sectional findings suggest that β-amyloid burden does not have a large effect on cognition in this subset of apparently healthy older people. The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B18C13</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cognition</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cognition</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cognición</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Protéine amyloïde β</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>β Amyloid protein</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Proteína amiloide β</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Démence d'Alzheimer</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mémoire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Memory</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Memoria</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Sénescence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Senescence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Senescencia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vieillissement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ageing</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Envejecimiento</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Imagerie médicale</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Medical imagery</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Imaginería médica</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Elderly</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Anciano</s0>
<s5>19</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>262</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004527 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 004527 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:11-0384044
   |texte=   Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study

Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri